Loading data for BHVN — first visit, this takes a few seconds.
Biohaven Ltd. (BHVN)
NYSE: BHVN
· Real-Time Price · USD
15.00
+0.28 (1.90%)
At close: Sep 10, 2026, 8:00 PM
The price, the headline numbers and the latest news, in one place.
Biohaven Ltd. (BHVN) Stock Price, Analysis & Data
No data available
| Bid | 0 |
| Market Cap | 1.93B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -587M |
| 3.17 | |
| -3.88 | |
| n/a | |
| -6.83 | |
| P/B (ttm) | 157.90 |
| P/S (ttm) | 0.00 |
| Earnings Date | Nov 9, 2026 |
| Ask | 0 |
| Volume | 2,817,147 |
| Avg. Volume (20D) | 2,991,901 |
| Open | 14.62 |
| Previous Close | 14.72 |
| Day's Range | 14.41 - 15.46 |
| 52-Week Range | 7.48 - 18.57 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About BHVN
Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develops BHV-1300, which is in Phase 2 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 2 clinical trial for treating IgA nephropathy; BHV-1600, which is in Phase 1 clinical trial for the treatment of peripartum c...
Industry Biotechnology
Sector Healthcare
IPO Date Sep 23, 2022
Employees 274
Stock Exchange NYSE
Ticker Symbol BHVN
Website https://www.biohaven.com
Financial Performance
In 2025, Biohaven's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -738.82M, a decrease of -12.71%.
Financial StatementsEarnings Surprise
Biohaven has released their quarterly earnings on Aug 10, 2026:
- Revenue of $0 misses estimates by $0, with NaN% YoY growth.
- EPS of -0.78 misses estimates by -0.17, with 52.15% YoY growth.
Biohaven Ltd. is scheduled to release its earnings on Nov 9, 2026, during market hours.
Analysts project revenue of ... Upgrade
Analysts project revenue of ... Upgrade
Page 1 of 2